Sofetabart mipitecan (LY4170156), an investigational folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), elicited strong antitumor activity in patients with recurrent ...

Presentation to include 3-year data from all cohorts of the Phase 1 AQUAx Clinical Study - Cohort-level data and individual patient data from bilateral and unilateral cohorts will be presented for ...

Sranan Gold Corp. (CSE: SRAN) (OTCQB: SRANF) (FSE: P84) ("Sranan" or the "Company") announces that it has commenced a 5,000-metre diamond drill program focused on the high-grade Poeketi Zone located 4 ...

Paclitaxel remains first-line for cutaneous angiosarcoma, but absence of validated second-line therapy creates a major unmet ...

Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.

Teachers can borrow the idea of halftime from sports by shifting exit tickets to earlier in the class, assessing how well ...

Safety featured universal TEAEs and 92% grade ≥3 events; anemia (39.5%) predominated, discontinuations were frequent, and ...

PYNNACLE enrolled heavily pretreated TP53 Y220C–mutant ovarian cancer (median four prior lines), including platinum-resistant ...

FFO per share growth -- 2.3% increase in the quarter and 4.8% growth year-to-date, both compared to prior-year periods, ...

Weiss Ratings Plus latest research outline what the company describes as a developing second phase of AI market activity - ...

Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.